UK-based drug development services company Ergomed has announced Board and Management changes.
Neil Clark will step down as a Director of Ergomed, moveing on to become Chief Executive Officer of Destiny Pharma, a company focused on the discovery, development and commercialisation of novel antimicrobials.
Clark will remain on the Board of Ergomed's subsidiary, PrimeVigilance, as a non-executive director and a consultant during the transition period.
Jan Petracek will step into the role of Chief Executive Officer of PrimeVigilance. Petracek joined Ergomed in November 2016 as CEO of European PharmInvent Services following its acquisition and subsequent integration into PrimeVigilance.
Miroslav Reljanovic, Chief Executive Officer of Ergomed, said:
“I would like to give my sincere thanks to Neil has helped the Company transition from a private company through the IPO process in 2014 and latterly, overseen a period of strong growth in PrimeVigilance. I wish him all the best in the next stage of his career.
“We are fortunate to have in the wings a replacement CEO of the calibre of Jan Petracek. As founder of PharmInvent and former regulator at EMA, his unique combination of entrepreneurship and specialist pharmacovigilance expertise will serve to drive forward our pharmacoviglance businesses.”
